MedTrace Logo

Effects of a 12-Week Recreational Football Program on Physical Activity Determinants in Adolescents

NCT07490249 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-03-24

No results posted yet for this study

Summary

Randomized controlled trial assessing the effects of a 12-week recreational football program on behavioral, psychosocial, environmental, and physical determinants of physical activity in male adolescents aged 10-13 years.

Conditions

  • Physical Inactivity

Interventions

BEHAVIORAL

Recreational Football Program

The intervention consists of a 12-week recreational football program delivered twice per week at the university's outdoor soccer field. Each 60-minute session includes a 10-minute warm-up followed by 50 minutes of small-sided, game-based football activities. Sessions are led by two trained coaches and an assistant under the supervision of the principal investigator. Heart rate is monitored using Polar H10 sensors, and a subsample of participants is tracked with GPS devices (GPEXE System) to quantify total distance and intensity zones. At the end of each session, participants report ratings of perceived exertion (Borg CR-10 Scale) and exercise enjoyment, providing immediate physiological and psychological response markers.

Sponsors & Collaborators

  • Rio de Janeiro State Research Supporting Foundation (FAPERJ)

    collaborator OTHER_GOV

  • Hospital Universitario Pedro Ernesto

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
10 Years
Max Age
13 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-03-31
Primary Completion
2026-09-30
Completion
2026-10-31

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07490249 on ClinicalTrials.gov